Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: A case report and review of the literature

Targeted Oncology

Volumn 3, Issue 2, 2008, Pages 127-130

  Moroni, Mauro ^a   Veronese, Silvio ^a   Sartore Bianchi, Andrea ^a   Artale, Salvatore ^a   Siena, Salvatore ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Colorectal cancer; EGFR; FISH; KRAS; Monoclonal antibodies

Indexed keywords

EID: 42449094896     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-008-0073-x     Document Type: Article

References (18)

1. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
2. Scartozzi M, Bearzi I, Beardi R, Mandolesi A, Fabris G, Cascinu S (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumor does not correlate with EGFR expression in related metastatic sites: implication for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22:4772-4778
3. Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995
4. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS-RAF signaling pathway impairs the response of metastatic colorectal cancers to anti EGFR antibody therapies. Cancer Res 67:2643-2648
5. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664
6. Chung KY, Shia J, Kemeny NE et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810
7. Pippas AW, Lenz HJ, Mayer RJ, Mirtsching B, Cohn AL, Windt P, Van Cutsem E (2005) Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy. J Clin Oncol 23 (Proc ASCO 2005): Abstract 3595
8. Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279-286
9. Sartore-Bianchi A, Moroni M, Veronese S et al (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238-3245
10. Frattini M, Saletti P, Romagnani E et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139-1145
11. Cappuzzo F, Finocchiaro G, Rossi E et al (2007) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol (in press), DOI 10.1093/annonc/mdm492
12. Gravalos C, Sastre J, Aranda E et al (2007) Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (mCRC) treated with single-agent cetuximab as first-line treatment. J Clin Oncol 25 (Proc ASCO 2007): Abstract 4120
13. Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237
14. Lenz HJ, Van Cutsem E, Khambata-Ford S et al (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914-1421
15. Finocchiaro G, Cappuzzo F, Jänne PA et al (2007) EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol 25 (Proc ASCO 2007): Abstract 4021
16. Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166-1169
17. De Roock W, De Schutter J, De Hertogh G et al (2007) KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab. J Clin Oncol 25 (Proc ASCO 2007): Abstract 4132
18. Schrag D (2004) The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 351:317-319